Ex­clu­sive: Saris­sa's board push drew lit­tle sup­port in Alk­er­mes share­hold­er vote

Saris­sa Cap­i­tal Man­age­ment lost its proxy bat­tle bad­ly against Irish drug­mak­er Alk­er­mes last week, ac­cord­ing to a fi­nal tal­ly of votes for board nom­i­nees.

Saris­sa’s CEO Alex Den­ner re­ceived sup­port from on­ly 24% of the 147 mil­lion shares vot­ed, ac­cord­ing to a com­pa­ny fil­ing re­viewed by End­points News. The in­vest­ment com­pa­ny put up three nom­i­nees to re­place Alk­er­mes board mem­bers, and has waged a long-run­ning cam­paign for changes at the drug com­pa­ny, which Den­ner has called mis­man­aged.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER